afinitor 10 mg
novartis pharma gmbh - germania - everolimus - compr. - 10 mg - inhibitori de protein-kinaza inhibitor selectiv al mtor
afinitor 5 mg
novartis pharma gmbh - germania - everolimus - compr. - 5 mg - inhibitori de protein-kinaza inhibitor selectiv al mtor
votubia
novartis pharma gmbh - germania - everolimus - compr. - 10mg - inhibitori de protein-kinaza inhibitor selectiv al mtor
votubia
novartis pharma gmbh - germania - everolimus - compr. - 2,5 mg - inhibitori de protein-kinaza inhibitor selectiv al mtor
votubia
novartis pharma gmbh - germania - everolimus - compr. - 5mg - inhibitori de protein-kinaza inhibitor selectiv al mtor
votubia 2 mg
novartis pharma gmbh - germania - everolimus - compr. pt. disp. orala - 2mg - inhibitori de protein-kinaza inhibitor selectiv al mtor
votubia 3 mg
novartis pharma gmbh - germania - everolimus - compr. pt. disp. orala - 3mg - inhibitori de protein-kinaza inhibitor selectiv al mtor
votubia 5 mg
novartis pharma gmbh - germania - everolimus - compr. pt. disp. orala - 5mg - inhibitori de protein-kinaza inhibitor selectiv al mtor
kisplyx
eisai gmbh - lenvatinib mesilate - carcinomul, celula renală - agenți antineoplazici - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.
fluzon 150 150 mg comprimate filmate
cadila pharmaceuticals limited - fluconazolum - comprimate filmate - 150 mg